Home  Media Press releases
|
|
|
| 9 March 2006 | 2006-03-09T00:00:00.0000000-00:00 |
| AstraZeneca commences patent infringement litigation against IVAX
AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals, Inc. and Zenith Laboratories, Inc. (collectively “IVAX”), and IVAX’s parent, Teva Pharmaceutical Industries Ltd. and its U.S. subsidiary, Teva Pharmaceuticals USA, for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium). | The lawsuit is in response to an Abbreviated New Drug Application filed by IVAX with the US Food and Drug Administration regarding IVAX’s intent to market a generic version of AstraZeneca’s NEXIUM in the US prior to the expiration of five AstraZeneca Patents: 5,714,504; 5,877,192; 6,369,085; 6,428,810; and 6,875,872. The expiration dates for these patents range from 2014 through to 2019.
AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting NEXIUM.
-Ends-
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Ed Seage, Tel: +1 302 886 4065
Jorgen Winroth, Tel + 1 212 579 0506
|
|
|